Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects with Advanced Cancer

Next Previous
Trial Profile

A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects with Advanced Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VLS 1488 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Sarcoma; Squamous cell cancer; Triple negative breast cancer; Uterine cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Volastra Therapeutics

Most Recent Events

  • 22 May 2025 Results presented in the Volastra Therapeutics Media Release.
  • 22 May 2025 According to a Volastra Therapeutics media release, Preliminary results from a first-in-human, phase I/II study of VLS-1488 will will be featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Monday, June 2, 2025, 8:00 AM- 9:30 AM CT
  • 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top